Live Breaking News & Updates on Adhera Therapeutics

Stay updated with breaking news from Adhera therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Biodexa Pharmaceuticals PLC: Preliminary Results for the Year Ended 31 December 2023

Biodexa Pharmaceuticals PLC: Preliminary Results for the Year Ended 31 December 2023
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , San Francisco , Russian Federation , Stephen Parker , Dennis Riedl , Monte Carlo , Simon Turton , Acta Neuropathol , Biosciences Inc , Company Issued Ordinary , Columbia University , University Of Alberta , Adss Of The Company , University Of Texas , Armistice Capital Master Fund Ltd , Company Employee Handbook , International Financial Reporting Standards Ifrss , Pfizer Inc , Company Ordinary , Parent Company , Registrar Of Companies , Adhera Therapeutics Inc , University Of California , Exchange Agreement , Biodexa Pharmaceuticals ,

Biodexa Pharmaceuticals - Foray into T1D expands business scope

Biodexa Pharmaceuticals - Foray into T1D expands business scope
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Stefan Klotter , Adhera Therapeutics , Die Performance Strategie , Assets Sie ,

Adhera Therapeutics, Inc. (OTCMKTS:ATRX) Sees Significant Growth in Short Interest

Adhera Therapeutics, Inc. (OTCMKTS:ATRX – Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 14,600 shares, a growth of 7,200.0% from the December 31st total of 200 shares. Based on an average trading volume of 317,100 shares, […] ....

Adhera Therapeutics Inc , Adhera Therapeutics Company Profile , Marina Biotech Inc , Adhera Therapeutics , Get Free Report , Marina Biotech , Adhera Therapeutics Daily , Otcmkts Atrx ,

Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option

Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

New York , United States , United Kingdom , Edison Group , Bukwang Pharmaceuticals Co Ltd , Prospectus Department , Biodexa Pharmaceuticals , Pfizer Inc , Exchange Agreement , Melior Pharmaceuticalsi Inc , Ladenburg Thalmann Co , Exchange Commission , Adhera Therapeutics Inc , Underwritten Public Offering , Including Full Exercise Of Overallotment , Typei Diabetes , Adhera Therapeutics , Depositary Share , Seriese Warrants , Classb Unit , Each Pre Funded Warrant , Pre Funded Warrants , License Agreement , Secured Noteholders , Depositary Shares , United States Securities ,

Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option

Biodexa Pharmaceuticals PLC, , a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the. ....

United States , New York , United Kingdom , Melior Pharmaceuticalsi Inc , Edison Group , Exchange Commission , Exchange Agreement , Biodexa Pharmaceuticals , Adhera Therapeutics Inc , Prospectus Department , Globenewswire Inc , Bukwang Pharmaceuticals Co Ltd , Pfizer Inc , Ladenburg Thalmann Co , Underwritten Public Offering , Including Full Exercise Of Overallotment , Typei Diabetes , Adhera Therapeutics , Depositary Share , Seriese Warrants , Each Pre Funded Warrant , Pre Funded Warrants , License Agreement , Secured Noteholders , Depositary Shares , States Securities ,